InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, releases a new version of LikelihoodProfiler.jl. LikelihoodProfiler represents a unified Julia package that can be used for practical identifiability analysis for complex computationally demanding QSP models.
Initially, LikelihoodProfiler.jl included a method (CICO) for estimating confidence intervals (CI) and assessing the practical identifiability of model parameters using the profile likelihood approach. Now LikelihoodProfiler package provides various state-of-the-art methods for profile likelihood analysis, including optimization-based and integration-based profiles, CI endpoints search, and more. These methods are now unified under a new interface, making it easier for users to switch between them. The results of LikelihoodProfiler.jl analysis can be used to further reduce the complexity and eliminate model’s uncertainty by implementing identifiable parametrizations and model reduction techniques.
Ivan Borisov, Senior Software Developer, comments on the new version of LikelihoodProfiler.jl, “This release marks the first version of the revamped package. We plan to introduce additional methods, improve interfaces, enhance documentation, and more to make the package more valuable to the community.”
LikelihoodProfiler package is open-source and freely available on GitHub: https://github.com/insysbio/LikelihoodProfiler.jl
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | March 2025 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
| |||||
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
|
17
|
18
|
19
1.
19 Mar 2025 15:40
The project aims at mechanistic modeling of antibodies to predict pharmacokinetics and target occupancy in cerebrospinal fluid
InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease
|
20
|
21
|
22
|
23
|
|
24
|
25
|
26
1.
26 Mar 2025 00:12
InSysBio to participate in AACR 2025
InSysBio announces its participation in AACR Annual Meeting 2025 which is to be held from April 25-30, 2025, at McCormick Place Convention Center, Chicago, Illinois, USA. InSysBio team is going to present their QSP modeling services and software to optimize drug development at Booth #4845 and 3 posters in frames of the Meeting
|
27
|
28
|
29
|
30
|
|
31
1.
31 Mar 2025 15:17
Now the Immunological Synapse submodels are meaningfully improved
InSysBio launches Immune Response Template (IRT) version 3.7.0. IRT represents a QSP platform of immune system, simultaneously, being a tool for development of models related to immune system. IRT v.3.7.0 gets a range of new features.
| ||||||
Thank you for your message! We will get back to you shortly.
